Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort

References

• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: US Department of Health and Human Services; December 1, 2009. Available at: HYPERLINK “http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf” http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed date: 1 October 2010).
   Google Scholar
• Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, . Durable efficacy of tipranavir–ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466–75.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Slater LN, Schwartz R, Kazanjian PH, Hathaway B, Wheeler D, . Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study. J Acquir Immune Defic Syndr 2007; 45:401–10.
   PubMedGoogle Scholar
• Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, . POWER 1 and 2 study groups. Efficacy and safety of darunavir–ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169–78.
   PubMed Web of Science ®Google Scholar
• Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, . Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother 2010;54:2473–9.
   PubMedGoogle Scholar
• Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, . Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008;22: 1389–97.
   PubMed Web of Science ®Google Scholar
• Mitsuya Y, Liu TF, Rhee SY, Fessel WJ, Shafer RW. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis 2007;196:1177–9.
   PubMedGoogle Scholar
• Koh Y, Amano M, Towata T, Danish M, Leshchenko-Yashchuk S, Das D, . In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J Virol 2010;84:11961–9.
   PubMed Web of Science ®Google Scholar
• Temesgen Z, Feinberg J. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis 2007;45:761–9.
   PubMed Web of Science ®Google Scholar
• Luna B, Townsend MU. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther 2007;29:2309–18.
   PubMedGoogle Scholar
• Pierone G Jr, Urban T, Martin A, Mieras J, Kantor C. Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir. HIV Clin Trials 2008;9:140–1.
   PubMed Web of Science ®Google Scholar
• Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arasteh K, . Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006;43:1347–56.
   PubMed Web of Science ®Google Scholar
• Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G Jr, . Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006;43: 1337–46.
   PubMed Web of Science ®Google Scholar
• Pugliese P, Cuzin L, Cabié A, Poizot-Martin I, Allavena C, Duvivier C, . A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med 2009;10: 504–11.
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, . Tipranavir–ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2008;52:3237–43.
   PubMed Web of Science ®Google Scholar
• Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, Scherer JR, . Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006;80:10794–801.
   PubMed Web of Science ®Google Scholar
• Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, . Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18:156–63.
   PubMedGoogle Scholar
• Schapiro JM, Scherer J, Boucher CA, Baxter JD, Tilke C, Perno CF, . Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. Antivir Ther 2010; 15:1011–9.
   PubMedGoogle Scholar
• Bethell R, Hall DB, Baxter J, Schapiro J, Boucher C, Scherer J. No effect of subtype on susceptibility and virological response to TPV/r for treatment experienced patients. Abstract A121. 17th International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Sitges, Spain, 10–14 June 2008. Antivir Ther 2008;13(Suppl 3):A121.
   Google Scholar
• Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC. Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure. BMC Infect Dis 2009;9:154.
   PubMedGoogle Scholar
• Baxter JD, Bhatti L, Coakley E, Bartczak J, McDonough M, Vinisko R, . Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: the UTILIZE study. Curr HIV Res 2010;8:347–54.
   PubMedGoogle Scholar
• Raffi F, Battegay M, Rusconi S, Opravil M, Blick G, Steigbigel RT, . Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007;21:1977–80.
   PubMed Web of Science ®Google Scholar
• Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, . Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008;65:5–18.
   PubMed Web of Science ®Google Scholar
• Hanley WD, Wenning LA, Moreau A, Kost JT, Mangin E, Shamp T, . Effect of tipranavir–ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009;53:2752–5.
   PubMed Web of Science ®Google Scholar
• Khanlou H, Allavena C, Billaud E, McKellar M, Reliquet V. Development of hepatic cytolysis after switching from enfuvirtide to raltegravir in virologically suppressed patients treated with tipranavir/ritonavir. Abstract TUPE0087. 17^th International AIDS Conference, Mexico City, Mexico, August 2008.
   Google Scholar
• Schöller M, Kraft M, Hoetelmans R, Vyncke V, Vandermeulen K, Peeters M, . Significant decrease in TMC125 exposures when co-administered with tipranavir (boosted with ritonavir) in healthy subjects. Abstract 583. 13^th Conference on Retroviruses and Opportunistic Infections, Denver, CO, USA, February 2006.
   Google Scholar